IDEX Corporation Q2 FY26 Earnings Analysis
Published 29 May 2026 | Machinery | Market Cap: ₹15.5K Cr
Price
₹210.03
Market Cap
₹15.5K Cr
P/E Ratio
31.2
Revenue Rank
Margin Rank
Earnings Summary
- Positive long-term growth expected, particularly beyond 2026, with strong involvement in emerging technologies and markets (Page 13). - IDEX expects continued solid growth beyond 2026, especially driven by its Health & Science Technologies (HST) segment with high single-digit to double-digit growth.
📊 Revenue & Sales Performance
Rank 3- Positive long-term growth expected, particularly beyond 2026, with strong involvement in emerging technologies and markets (Page 13). - HST segment driving high single-digit to double-digit growth, supported by backlog expansion and advantaged markets like semiconductor, data centers, and space & defense (Pages 4, 8). - FMT showing solid performance with strong water platform growth, but overall flat outlook due to macro uncertainties (Pages 4, 7). - FSDP experiencing slight decline but with pockets of growth in fire and safety (Page 4). - Overall organic revenue growth guidance for 2026 revised upward to 3%-4%, with HST growth offsetting flatter FMT and FSDP (Page 3). - Continued innovation and multiple entry points into growth markets, including optical switching, thermal management, and AI-integrated water solutions (Page 13).
📈 Profitability & Margins
Rank 3- IDEX expects continued solid growth beyond 2026, especially driven by its Health & Science Technologies (HST) segment with high single-digit to double-digit growth. - Full year 2026 guidance raised to 3-4% organic growth, up from 1-2%, driven by strong HST momentum and stable outlooks in other segments. - Adjusted EBITDA margin for 2026 expected to be 26.5% to 27%, with margin expansion in HST partially offset by challenges in other segments. - Adjusted EPS guidance for 2026 increased by $0.20 to a range of $8.35 to $8.55, representing mid- to high single-digit growth year-over-year. - Incremental margins in HST are currently in the low to mid-30% range, expected to improve as acquired businesses scale and life sciences growth picks up. - Beyond 2026, investments in advantaged markets like space, data centers, and semiconductors provide a strong runway for sustained earnings growth.
🏗️ Capital Expenditure Plans
Yes- IDEX expects an increase in CapEx for 2026, supporting overall growth, especially in the HST segment and some other growth platforms (Pages 13-14). - The rise in CapEx aligns with growth rates increasing rather than a shift toward more capital-intensive operations (Page 14). - There are no major single large CapEx projects; investments are spread across various businesses with a focus on equipment and automation to support growing demand (Pages 13-14). - The company emphasizes investments in technology and innovation with relatively low capital intensity, enabling agility and faster technology deployment, particularly in space and defense sectors (Page 14). - Internal optimization through the "8020" initiative helps offset CapEx increases by reallocating capital from lower-growth areas to faster-growing applications (Page 13). - IDEX continues to pursue bolt-on tuck-in acquisitions to expand advantaged market presence and capabilities (Page 14).
💰 Fundraising & Capital Structure
No information- There is no mention of any new fundraising through debt or equity in the provided transcript. - The company ended Q1 2026 with strong liquidity of approximately $1.1 billion. - Their gross leverage ratio is roughly 2x as of the end of Q1 2026. - They maintain a balanced capital deployment strategy focusing on organic investments, bolt-on M&A, and returning capital to shareholders. - They repurchased $76 million of shares in the quarter and plan to maintain this repurchase pace through 2026. - No indications given of plans to issue new debt or equity in the near term; emphasis is on managing growth with current resources and maintaining a strong balance sheet for flexibility.
📋 Order Book & Pipeline
Yes- HST segment showed strong backlog growth, driven by faster-growing order wins and novel solutions in advantaged markets like semiconductor OEM and data centers. - Increased visibility into order backlog, with customers providing good forward-looking insights for capital and resource planning. - Backlog growth supports confidence in continued growth beyond a 12-month horizon. - FMT and FSDP have less visibility due to the rapid fulfillment nature of their businesses. - Overall, organic orders grew approximately 10% in the quarter, led by HST's 17% order growth year-over-year. - Orders in FMT grew 9% organically; FSDP orders declined 4% organically. - Approximately 50% of orders are typically booked entering any quarter, with strong HST order activity building backlog for better financial outlook.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were IDEX Corporation Q2 FY26 results?
- Positive long-term growth expected, particularly beyond 2026, with strong involvement in emerging technologies and markets (Page 13). - IDEX expects continued solid growth beyond 2026, especially driven by its Health & Science Technologies (HST) segment with high single-digit to double-digit growth.
What is IDEX Corporation share price analysis?
IDEX Corporation currently shows a below-average growth signal. The stock trades at a P/E of 31.2 with a market cap of $15,545. Investors should review the full earnings analysis for detailed insights.
Is IDEX Corporation planning capital expenditure?
- IDEX expects an increase in CapEx for 2026, supporting overall growth, especially in the HST segment and some other growth platforms (Pages 13-14).
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
